UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum

PRINCETON, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the third quarter ended September 30, 2025, and provided an overview of recent developments.

Read more at globenewswire.com